ROS1 and non-small cell lung carcinoma: Crizotinib is a first-generation tyrosine kinase inhibitor initially designed to target c-Met [11], of which the (R)-enantiomer has been approved for the treatment of ALK (anaplastic lymphoma kinase)- and ROS-1 (ROS proto-oncogene 1)-positive advanced NSCLC (non-small cell lung carcinoma) as a multi-target inhibitor.